Abstract Reports of the development of antimicrobial resistance by Bordetella pertussis to macrolides in the United States and Taiwan, together with a recent increase in pertussis notifications and laboratory-confirmed cases in England and Wales in 2008, prompted the examination of historical and recent clinical isolates from patients for evidence of such resistance in our collection. Isolates submitted to our laboratory as part of the enhanced surveillance scheme for pertussis, from 2001 to 2009, were tested against three agents, erythromycin, clarithromycin and azithromycin, by the Etest (bioMérieux) method. All isolates (n=583) were fully susceptible to all three agents tested (minimum inhibitory concentrations [MICs] ≤0.125 µg/ml). All but one strain (582/583) had MICs of ≤0.064 for all three agents. The control strain of B. pertussis A228 (from the Centers for Disease Control and Prevention [CDC], Atlanta, Georgia, USA) with a resistant phenotype had an MIC of >256 µg/ml. Although no evidence of resistance was found in the strains tested from the United Kingdom, screening for antimicrobial resistance of B. pertussis may be warranted in cases that are unresponsive to macrolide treatment and to provide early warning of such emergence in the future. These reports and a recent increase in notifications [5] prompted this examination of our collection of historical and recent clinical isolates of B. pertussis. Clinical isolates of B. pertussis are submitted to our laboratory, the Respiratory and Systemic Infection Laboratory (RSIL), as part of the enhanced surveillance scheme for pertussis for England and Wales. Our laboratory also receives isolates from Ireland, Northern Ireland and Scotland, and these were also included in this analysis. In this study, we report the susceptibility testing to erythromycin, clarithromycin and azithromycin by the Etest (bioMérieux) method for 583 B. pertussis clinical isolates that represent the majority (≥95%) of isolates submitted to the RSIL between January 2004 and December 2009, and a selected number of isolates from September 2001 to December 2003. The years of isolation and numbers of strains isolated were as follows : 2001, 2; 2002, 40; 2003, 17; 2004, 68; 2005, 110; 2006, 53; 2007, 69; 2008, 134; and 2009, 90. Prior to testing, isolates were initially subcultured into charcoal blood agar (Media Services, Central Public Health Laboratory, London) to check for purity and incubated at 37°C for 24-72 h. Mueller-Hinton agar plates supplemented with 10% horse blood (Oxoid, CPHL Media Services), 25 ml final volume, 90 mm triple-vented Petri dish (Greiner Bio-One Ltd.), were inoculated by the resuspension of bacterial growth as recommended for Bordetella spp. testing, but modified to use a higher MacFarland equivalent of 8, to achieve the semi-confluent growth required. E-strips (bioMérieux) were equilibrated to room temperature and then carefully applied to the centre of each agar plate. Inoculated plates were incubated for 48 h to 7 days in a moist atmosphere at 37°C.
Susceptibility testing of Bordetella spp., including B. pertussis clinical isolates, is not routinely performed and, prior to 1994, resistance to erythromycin in B. pertussis had not been observed [1] . However, since then, there have been a few reports presenting the emergence of erythromycin-resistant B. pertussis isolates in the USA [2, 3] and one in Taiwan [4] .
These reports and a recent increase in notifications [5] prompted this examination of our collection of historical and recent clinical isolates of B. pertussis. Clinical isolates of B. pertussis are submitted to our laboratory, the Respiratory and Systemic Infection Laboratory (RSIL), as part of the enhanced surveillance scheme for pertussis for England and Wales. Our laboratory also receives isolates from Ireland, Northern Ireland and Scotland, and these were also included in this analysis. In this study, we report the susceptibility testing to erythromycin, clarithromycin and azithromycin by the Prior to testing, isolates were initially subcultured into charcoal blood agar (Media Services, Central Public Health Laboratory, London) to check for purity and incubated at 37°C for 24-72 h. Mueller-Hinton agar plates supplemented with 10% horse blood (Oxoid, CPHL Media Services), 25 ml final volume, 90 mm triple-vented Petri dish (Greiner Bio-One Ltd.), were inoculated by the resuspension of bacterial growth as recommended for Bordetella spp. testing, but modified to use a higher MacFarland equivalent of 8, to achieve the semi-confluent growth required. E-strips (bioMérieux) were equilibrated to room temperature and then carefully applied to the centre of each agar plate. Inoculated plates were incubated for 48 h to 7 days in a moist atmosphere at 37°C. The MIC values of test and control strains of B. pertussis were recorded at 72 h, following the manufacturer's instructions. In addition, the plates were examined at 7 days to check for the appearance of the heterogenous phenotype for erythromycin resistance [6] . Isolates of B. pertussis with MICs of >256 µg/ml after 72 h were considered to be resistant [2] .
The B. pertussis isolates tested (from 2001-2009) included different serotypes (11 serotype 1,2; 569 serotype 1,3; and 11 untypeable) from different age groups (<3 months, 348; 3-5 months, 90; 6-11 months, 23; 1-4 years, 1; 5-9 years, 5; 10-14 years, 10; ≥15 years, 15; unknown, 24) with a male:female ratio of 1:1.1. Isolates were received from geographically diverse locations within the United Kingdom and were known to include a number of distinct genotypic types, i.e. pertactin, pertussis toxin, multi-locus variable number of tandem repeats analysis [7] and authors' unpublished data. All isolates (523/523) were susceptible to all three agents tested (MICs≤0.125 µg/ml) with the Etest method. An example of the results obtained is shown in Fig. 1 . All isolates had MICs of ≤0.064 µg/ml with both erythromycin and azithromycin and one strain had an MIC of 0.125 µg/ml with clarithromycin. These results are comparable to those obtained with these agents in a study of 36 strains from Northern California by the Etest method [8] . No evidence of heterogeneous resistance was found. The erythromycin-resistant B. pertussis A228 strain always yielded an MIC value of >256 µg/ml with all three agents, which is consistent with that previously reported [2] . The control strain NCTC6571 gave results consistent with target MICs for all three of these agents, i.e. 0.12 µg/ml [9] .
Macrolides (especially erythromycin) remain the current antibiotics of choice for post-exposure prophylaxis and treatment of pertussis infection [10] . Azithromycin is also recommended for the prophylaxis of neonates, as it is associated with fewer adverse effects [11] . The data from this study confirm that the current guidelines for macrolide treatment remain appropriate for B. pertussis [11] [12] [13] . There are few documented occurrences of B. pertussis resistance to macrolides to date and the frequency of occurrence is estimated to be low (<1%) [6] . Although no evidence of macrolide resistance was found in this study of a large (n=583) number of clinical isolates from the United Kingdom, sensitivity testing for B. pertussis may be warranted in cases that are unresponsive to macrolide treatment and to provide early warning of the emergence of such resistance in the future. The mechanism of resistance was proposed to be due to a mutation of the erythromycin binding site in the 23S rRNA gene, and the identification of this and other potential resistance mechanisms should allow genotypic testing and facilitate more rapid screening of large numbers of isolates or clinical specimens in the future.
